Respiratory distress syndrome (RDS) is a leading cause of mortality and morbidity in preterm infants. Surfactant replacement therapy has been widely used to prevent and treat RDS in these newborns and has now become a standard of care. First-generation synthetic surfactants such as Exosurf did not contain any surfactant protein. This disadvantage was overcome with animal-derived surfactant preparations which contain specific proteins but has the limitation of being derived from animal sources. This has led to development of newer synthetic surfactants such as lucinactant (Surfaxin, Discovery Laboratories, Philadelphia) which contains the protein B mimic synthetic peptide, sinapultide. Recent phase 3 clinical trials with Surfaxin show promising results with similar efficacy as animal derived surfactants and yet avoiding the disadvantage associated with animal products. The purpose of this paper is to summarise results of recent clinical trials of Surfaxin use in newborns with RDS.
Introduction
Respiratory distress syndrome (RDS) still remains a leading cause of mortality and morbidity in preterm infants. Natural surfactant is produced by type II epithelial cells. Few of these cells are present in the foetus during the second trimester, but they increase in numbers as the foetus approaches term gestation. It is therefore not surprising that the incidence and severity of RDS is inversely proportional to gestational age. Incidence of RDS varies from 25% at 32 weeks gestation to over 80% among babies born at 24 weeks. RDS is characterised by surfactant deficiency leading to higher surface tension at the alveolar surface, widespread atelectasis and decreased available surface area for gas exchange. Furthermore, this leads to poor compliance, increased resistance, ventilation perfusion mismatch, impaired gas exchange and increased work of breathing [Donn and Sinha, 2006] . Surfactant replacement therapy with mechanical ventilatory support and supplemental oxygen ameliorates these conditions and therefore remains the mainstay of treatment for RDS. Randomised control trials have consistently shown that intratracheal administration of surfactants leads to improved survival and reduced incidence of complications in preterm infants [Soll, 1997; Soll, 2004; Soll and Blanco, 2001] .
Pulmonary surfactants
Pulmonary surfactant is a complex mixture of phospholipids (85%), neutral lipids and specific proteins (10%). Its primary function is to decrease the surface tension at alveolar level thus preventing smaller airways from collapsing at end-expiration. Dipalmitoyl-phosphatidylcholine (DPPC) is the main phospholipid which forms a stable monolayer within alveoli. Phospholipids alone, however, do not make up for all the biophysical properties of pulmonary surfactants. The contribution of surfactant proteins, especially the low-molecular-weight surfactant proteins SP-B and SP-C are essential for structural organisation and functional durability of surfactant by allowing rapid dispersion of phospholipids at the air-liquid interface and bringing about sustained reduction in surface tension after dynamic compression. SP-B tends to reduce surface tension to a greater degree than SP-C in in vitro experiments. SP-B is also responsible for both intra-and extracellular regulation of surfactant functions and is essential for proper expression of SP-C. Congenital absence of SP-B results in lethal respiratory failure presenting soon after birth. Compared with this, SP-C deficiency does not lead to respiratory failure at birth but may result in interstitial lung disease in later childhood. A number of recent reviews have underlined the effects of SP-B and SP-C protein mutations on lung function [Cole et al. 2001 ]. There are two other surfactant proteins, SP-A and SP-D, which are only marginally involved in the surface tension lowering ability of pulmonary surfactants but play an important role in innate host defence responses to microbial bacterial invasion.
Classification of exogenous surfactants
Exogenous surfactant preparations are classified mainly based on their source, whether animalderived or synthetic, and the presence or absence of protein in their composition.
First-generation synthetic surfactants
These include Exosurf (colfoscenil palmitate) and are mainly composed of DPPC and do not contain any protein. Exosurf has been the most widely used surfactant in this class. The other preparation, ALEC (pumactant) was withdrawn from the market about 5 years ago.
Animal-derived surfactants
These are derived mainly from lung mince or lung lavage of cows and pigs. As they are subsequently extracted with organic solvents, it is a misnomer to call them 'natural' surfactants. In addition to phospholipids (80%) as the main gradient, they all contain variable amounts of surfactant proteins Sp-B and Sp-C, but not Sp-A or Sp-D. The commonly available animal surfactants in use are Survanta, Infasurf, and Alveofact (all derived from cows); and Curosurf (derived from pigs). There are some other products available but experience is limited to specific regions. Individual preparations still have significant variability in the concentration of phospholipids and other constituents.
Newer synthetic surfactants
These synthetic surfactants contain phospholipids as well as synthetic peptide. Surfaxin (lucinactant) is composed of DPPC, POPG (palmitoyloleoyl phosphatidylglycerol), palmitic acid and synthetic peptide KL4 (sinapultide) which has structural similarities to one of the domains of SP-B as described below. Another synthetic surfactant composed of DPCC, POPG, palmitic and recombinant SP-C has been developed but there are no clinical trials using this preparation in newborns.
Randomised control trials have consistently shown that any form of surfactant replacement therapy leads to reduction in morbidity and mortality related to RDS whether used for treatment or prophylaxis [Soll, 1997; Soll, 2004; Soll and Blanco, 2001] . However, while both types of surfactant are effective in the treatment and prevention of RDS, a metaanalysis showed that the use of animal-derived surfactant was associated with fewer deaths [number need to treat (NNT) ¼ 37] and pneumothoraces (NNT ¼ 20), compared with synthetic surfactants that did not contain proteins [Soll and Blanco, 2001] . This advantage of animal-derived surfactants was attributed to the fact that they contained surfactant proteins that were not present in the first-generation synthetic surfactants. The authors did not report any improvement in the incidence of bronchopulmonary dysplasia (BPD). While interpreting the results of such meta-analysis, it is important to consider a number of factors such as the heterogeneity of patient population, entry criteria, study design and primary outcomes as well as whether the trials were masked and what doses were used. There were important differences in the characteristics of individual studies included in this meta-analysis. With publication of more recent trials it is now possible to have direct comparison between individual surfactant preparations, particularly with respect to hard outcomes such as mortality [Moya and Maturana, 2007; Pfister et al. 2007 ].
Animal-derived surfactants are still the most widely used preparation in the developed countries. Their main advantage relates to presence of surfactant protein Sp-B and fast onset of action. Nonetheless they may have certain disadvantages as well. Depending on the method of extraction there is wide variability in the key constituents such as surfactant proteins from batch to batch. Like any other medicinal product containing animal protein, they carry the potential risk of transmission of infectious agent as well as exposure to foreign proteins, although this has not been reported in the neonatal population. The development of newer synthetic surfactants with artificial peptides should overcome these difficulties. Surfaxin (lucinactant) is one such preparation containing phospholipids and a high concentration of a new peptide (sinapultide), a 21-amino acid synthetic peptide, which mimics the actions of human Sp-B. Although it has been suggested that this peptide forms a transmembrane helix and therefore more likely mimics Sp-C, this structural orientation is seen only in phospholipid bilayers, and not in the physiologic phospholipid monolayer in vivo, where the sinapultide spatial structure resembles one of the amphipathic domains of Sp-B. Indeed, very recent data using 31 P NMR and 2 H NMR show that the KL 4 peptide lies parallel to the polar head groups under physiological conditions, and even in DPPC/POPG bilayers as described originally. Moreover, lucinactant has been shown to reduce surface tension as well as or better than animal-derived surfactants [Manalo et al. 1996] , and its efficacy has already been proven in clinical trials.
Surfaxin remains in the gel state when stored at 4 C and changes to a liquid state when warmed to 44 C, in about 15 minutes. It cools to body temperature quickly and is then administered through an endotracheal tube. After initial warming, it remains in liquid form for a number of days, even after being refrigerated. The recommended dose of 175 mg/kg of phospholipid (5.8 ml/kg) results in a higher dosing volume than other surfactants. However, this did not led to any higher incidence of side-effects or intolerance during administration in clinical trials. It may be argued that a larger volume of surfactant may in fact facilitate bulk diffusion and even spreading to distal areas of the lung .
Clinical trials of Surfaxin
One phase 1/2 clinic trial and two large phase 3 randomised clinical trials have been published so far comparing Surfaxin with both animalderived as well as first-generation synthetic surfactant, Exosurf, in prevention of RDS. Both trials were masked and studied populations were followed up to 1 year of age to determine longer-term pulmonary and neurodevelopment outcomes which were not reported by any other trial of surfactant in the past.
SELECT Trial (safety and effectiveness of lucinactant versus Exosurf in a clinical trial of RDS)
This phase 3 multinational clinical trial compared the safety and efficacy of lucinactant to colfosceril palmitate (Exosurf). Beractant (Survanta) was also used in the reference arm. Preterm infants under 32 weeks' gestation between birth weight of 600 and 1200 g were enrolled to receive one of the surfactant preparations in a 2-2-1 scheme within 20-30 minutes of birth. The primary outcomes were incidence of RDS at 24 hours and deaths related to RDS in the first 2 weeks. Secondary outcomes included all-cause mortality and CLD. A total of 1294 infants were recruited in this large doubleblinded study; 527 in the treatment arm received Surfaxin, 509 in the control arm received Exosurf and 258 in the reference arm received Survanta. Surfaxin was used at a dose of 175 mg/kg of phospholipids (5.8 ml/kg volume) and the comparator surfactants were given according to manufacturer's recommendations. The side-effects, if any, during administration were recorded and no crossover use of surfactant was allowed. Survival without CLD was reported (supplemental oxygen requirement at 28 days as well as 36 weeks' corrected gestation). The mean gestational age and birth weight of infants recruited were 28 weeks and 970 g respectively. Antenatal steroid uptake was between 74% and 79%. In this trial, there were significantly fewer cases of RDS at 24 hours in Surfaxin-treated infants as compared with Exosurf (39.1% vs 47.2%; odds ratio 0.68; 95% CI 0.52-0.89); and reduced incidence of RDS-related deaths at day 14 in the Surfaxin-treated infants compared with Exosurf (4.7% vs 9.4%; odds ratio 0.43; 95% CI 0.25-0.73) and Survanta (4.7% vs 10.5%; odds ratio 0.35; 95% CI 0.18-0.66). Similarly BPD at 36 weeks' corrected gestation was significantly lower in the Surfaxin group compared with Exosurf (40.2% vs 45.0%; odds ratio 0.75; 95% CI 0.56-0.99). Although there was no difference in the efficacy of Surfaxin and Survanta against RDS at 24 hours, all-cause mortality was lower in Surfaxin-treated infants compared with those treated with Survanta (odds ratio 0.67; 95% CI 0.45-1.00). Sideeffects during administration varied between 7% and 27% of infants and some of these were slightly more common in the Surfaxin group as compared with Survanta. This is by far the largest surfactant comparison trials conducted to date and provides the only data comparing prophylactic use of Survanta vs Exosurf. There were no differences reported in pneumothorax, BPD or other complications for prematurity between the groups [Moya et al. 2005] .
STAR (Surfaxin therapy against RDS) trial
This double-blinded multinational phase 3 randomised clinical trial recruited 252 preterm infants of 24-28 weeks gestation and birth weight between 600 and 1250 g to receive Surfaxin in the treatment arm as compared to Poractant Alfa (Curosurf) in the control arm, within 30 minutes of birth [Sinha et al. 2005 ]. The primary outcome measure was survival without chronic lung disease in the first 28 days. Secondary outcomes included mortality and common complications of prematurity. This study used a noninferiority design because of concerns relating to ethics of conducting a placebo-controlled trial in the current age. This meant that statistical significance would be achieved if the lower margin of 95% confidence interval of the observed treatment difference in the current study was more than 50% of that found in the original Curosurf vs placebo trial. This study was conducted in 22 NICUS in Europe and North America between 2001 and 2003. In a masked design, both surfactants were administered a similar dose of phospholipids (175 mg/kg of Surfaxin and 175 mg/kg of Curosurf). No crossover use of surfactant was permitted and side-effects relating to administration were recorded. Clinical diagnosis of BPD was established by the need for supplemental oxygen or artificial respiratory support at both 28 days and 36 weeks' corrected age. All deaths before discharge were reported. The mean gestational age and birth weight of recruited infants were 27 weeks and 930 g respectively. Survival without CLD through 28 days was 37.8% (95% CI; 29.1 to 46.5%) for the treatment group as compared with 33.1% (95% CI; 24.8-41.3%) for the control group. The treatment difference (Surfaxin minus poractant alpha) was À4.7% (95% CI À7.3 to þ16.8%) and the lower margin of 95% confidence interval (À7.3%) was greater than the À14.5% limit needed to achieve statistical noninferiority. The treatment difference of 4.7% with 99% confidence interval lower margin of À11% was still greater than the À14.5% limit needed to achieve statistical noninferiority. There was no statistically significant difference between the groups with respect to specified secondary outcomes such as death and BPD at 36 weeks' postmenstrual age, pulmonary haemorrhage, pneumothorax, patent ductus arteriosus, clinical sepsis, intraventricular haemorrhage, periventricular leucomalacia, necrotising enterocolitis and stage III or greater retinopathy of prematurity. There was no difference between groups with respect to serious adverse events during the course of the trial, particularly in the occurrence of oxygen desaturation, bradycardia or apnoea or the need to discontinue surfactant administration at any stage. Both drugs were comparable with respect to the degree of respiratory support including supplemental oxygen in the first 72 hours after surfactant administration as well as subsequently. A possible limitation of this study was the smaller sample size than originally estimated as the study was halted because of slow recruitment despite extending the duration of the trial. However, this decision was made without unmasking of treatment assignments or prior sequential or other interim analysis. The power of the study is a concept that is more appropriate for study design and is meaningful before final analysis of the data. After the study is completed and final analysis is performed, it is not a factor that has an impact on the interpretation of statistically significant results. The fact that noninferiority of Surfaxin to Curosurf was established, both at 95% and 99% confidence intervals and even with half the sample, is noteworthy. Moreover, this trial still stands out as one of the largest reported trials involving Curosurf and the first ever to show comparison of Curosurf against another surfactant using a prophylactic approach.
Altogether there were 650 babies in the Surfaxin group in both SELECT and STAR trials and their combined data for long-term survival, neurodevelopmental and pulmonary outcomes at 1 year corrected age against those receiving either Curosurf or Survanta have been published ]. Survival through 1 year corrected age still favoured the Surfaxin group versus those receiving animal-derived surfactants [74.0% and 70.4% respectively (p ¼ 0.05)]. This improved survival was not at the expense of adverse neurological status at 1 year, which was comparable between the groups. No other surfactant trials so far have reported long-term outcomes and it is reassuring to know that in these trials, Surfaxin performed better than the first-generation synthetic surfactant such as Exosurf and at least as good as currently available animal-derived surfactants [Engle et al. 2008; Pfister et al. 2007 ].
Further developments in surfactant therapy
Although all forms of exogenous surfactant therapy seem beneficial towards reducing the incidence and severity of RDS, it requires placement of a tube in the trachea which is an invasive process and can cause harm to babies. This has led to an increasing interest in evaluating alternative strategies aimed at avoiding intubation and giving surfactant in an aerosolised form through a device such as a continuous positive airway pressure (CPAP) machine. However, for this to be effective, the aerosolisation process must create the particles of appropriate size and the particles must be able to reaggregate and maintain or regain their biological activity. Aerosurf (an aerosolised form of lucinactant) has been shown to survive the aerosolisation process [Johnson et al. 2007; Mazela et al. 2007 ].
The only human neonatal clinical evaluation of Aerosurf to date has been the pilot trial of Finer et al. [2006] . Four US centres participated. Seventeen preterm infants were studied. Birth weights ranged from 1033 to 2296 g, and gestational ages ranged from 28 to 32 weeks, with 6 infants 28-29 weeks, and 11 infants 30-32 weeks. Eleven infants (64%) were successfully treated with a single administration. Only one infant required the maximal four doses. All of the infants survived, but only six required subsequent endotracheal intubation and intratracheal surfactant administration. The reduction in the fraction of inspired oxygen was comparable with that seen in most intratracheal surfactant trials. The rate of RDS at 24 hours was 24% and the rate of bronchopulmonary dysplasia at 28 days was 11.7%. No major problems related to safety or tolerability were encountered. Having established proof of concept, there is now a need for larger controlled clinical trials to prove the efficacy of Aerosurf as this will have significant impact on clinical practice not only dealing with RDS in preterm babies but also in older populations with a variety of respiratory illnesses.
Conclusion
RDS remains a major cause of mortality and morbidity in the preterm infants. Surfactant replacement therapy has led to a dramatic improvement in both survival and major morbidity relating to RDS. So far clinicians had limited options available in choosing between animal-derived surfactants with inherent disadvantages of being an animal product, or firstgeneration synthetic products that performed less well owing to the absence of surfactant protein.
Recent large randomised control trials have shown Surfaxin to be safe and efficacious and clearly superior to the first-generation synthetic surfactants and at least as effective, if not better, than animal-derived surfactants. Although Surfaxin is awaiting approval by the regulatory agencies for use in clinical practice, the evolution of peptide containing synthetic surfactant follows a similar trend with other medicinal products such as insulin and human growth hormone, which have evolved from animal sources to effective, synthetic sources of greater purity without risks of transmission of infectious agents. Moreover, the fact that synthetic surfactants can be produced in large amounts repeatedly with similar consistency at a relatively lower cost, holds much promise for the expanded use of Surfaxin in a number of other respiratory conditions such as meconium aspiration syndrome and pneumonia as well as its availability in those parts of the world where economic constraints have so far precluded the use of exogenous surfactant therapy resulting in unacceptably high perinatal mortality rates.
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